Meningioma Overview

Save information for later
Sign Up

Learn About Meningioma

View Main Condition: Brain Tumor

What is the definition of Meningioma?
Meningiomas are tumors that originate in the meninges, the membranes that surround the brain and spinal cord. Most Meningiomas are not cancerous (benign), though a minority of Meningiomas can be classified as atypical or cancerous (malignant). Though rare, malignant Meningiomas can be highly aggressive. However, even benign Meningiomas can cause problems if their growth affects neighboring areas of the brain. Though most Meningiomas grow slowly, there is no way to predict the rate of growth for a particular Meningioma or to know how long a specific Meningioma was growing before it was diagnosed. Signs and symptoms can vary but may include seizures, headaches, weakness in the arms and legs, and vision loss. Sometimes memory loss, carelessness, and unsteadiness are the only symptoms.
What are the alternative names for Meningioma?
  • Meningioma
Who are the top Meningioma Local Doctors?
Elite in Meningioma
Dr. Douglas S. Kondziolka
Neurosurgery
Elite in Meningioma
Dr. Douglas S. Kondziolka
Neurosurgery

New York University

111 Broadway, Fl 2, 
New York, NY 
212-263-9701
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Douglas Kondziolka is a Neurosurgery provider in New York, New York. Dr. Kondziolka is rated as an Elite provider by MediFind in the treatment of Meningioma. His top areas of expertise are Schwannoma, Acoustic Neuroma, Arteriovenous Malformation, Gamma Knife Radiosurgery, and Rhizotomy.

Elite in Meningioma
Dr. Vikram C. Prabhu
Neurosurgery
Elite in Meningioma
Dr. Vikram C. Prabhu
Neurosurgery

Loyola University Medical Center

2160 S 1st Ave, 
Maywood, IL 
708-216-9000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Vikram Prabhu is a Neurosurgery provider in Maywood, Illinois. Dr. Prabhu is rated as an Elite provider by MediFind in the treatment of Meningioma. His top areas of expertise are Meningioma, Familial Porencephaly, Hydrocephalus, Awake Craniotomy, and Osteotomy. Dr. Prabhu is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Meningioma
Dr. John G. Golfinos
Neurosurgery
Elite in Meningioma
Dr. John G. Golfinos
Neurosurgery

New York University

550 1st Ave, 
New York, NY 
212-263-7300
Languages Spoken:
English
See accepted insurances

John Golfinos is a Neurosurgery provider in New York, New York. Dr. Golfinos is rated as an Elite provider by MediFind in the treatment of Meningioma. His top areas of expertise are Acoustic Neuroma, Schwannoma, Meningioma, Gamma Knife Radiosurgery, and Awake Craniotomy.

View All Doctors
What are the latest Meningioma Clinical Trials?
A Multicenter Observational Study of GammaTile™ Surgically Targeted Radiation Therapy (STaRT) in Intracranial Brain Neoplasms
A Multicenter Observational Study of GammaTile™ Surgically Targeted Radiation Therapy (STaRT) in Intracranial Brain Neoplasms
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Device

Summary: The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Who is this study for: Patients with progressive meningiomas with SMO/ AKT/ NF2/CDK pathway mutations
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib
Study Phase: Phase 2

Summary: This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 11, 2022
Published By: Genetic and Rare Diseases Informnation Center